Cheng Daye, Kong Hong, Li Yunhui
Department of Transfusion, The First Hospital of China Medical University, North Nanjing Street, No. 155, Shenyang, 110001, Liaoning Province, People's Republic of China,
Eur Arch Otorhinolaryngol. 2014 Mar;271(3):503-9. doi: 10.1007/s00405-013-2580-3. Epub 2013 Jun 9.
Nasopharyngeal carcinoma (NPC) is one of the leading causes of cancer related death in China. One of the reasons is the absence of tumor specific prognostic markers. The aim of this study was to examine the prognostic values of interleukin-8 (IL-8) and matrix metalloproteinase-9 (MMP-9) in NPC patients. A total of 99 consecutive NPC patients and 40 healthy controls were recruited for this study. Serum levels of IL-8 and MMP-9 were evaluated in NPC patients who were followed up for 5 years. The serum levels of IL-8 and MMP-9 in NPC patients were significantly higher than those in healthy controls (IL-8 26.3 [2.9-68.0] ng/ml vs. 20.3 [2.3-38.6] ng/ml, P < 0.001; MMP-9 23.5 [3.6-52.1] ng/ml vs. 17.3 [2.6-36.9] ng/ml, P = 0.002), respectively. The serum levels of IL-8 and MMP-9 were positively correlated with the N classification (IL-8, P = 0.041, and MMP-9, P < 0.001, respectively) and clinical stage (IL-8, P = 0.022, and MMP-9, P < 0.001, respectively) in NPC patients. Analysis using the Kaplan-Meier method indicated that patients with high levels of IL-8 or MMP-9 had significantly shorter overall survival (OS) (IL-8, P = 0.012; MMP-9, P < 0.001) and disease-free survival (DFS) (IL-8, P = 0.021; MMP-9, P = 0.003) time than those with low levels of MMP-9 or IL-8. Univariate and multivariate analysis revealed elevated MMP-9 level was an independent predictor of shorter OS and DFS. Both MMP-9 and IL-8 are involved in NPC progression. MMP-9 in serum may be the clinically useful indicator for prognostic evaluation in NPC patients.
鼻咽癌（NPC）是中国癌症相关死亡的主要原因之一。原因之一是缺乏肿瘤特异性预后标志物。本研究的目的是检测白细胞介素-8（IL-8）和基质金属蛋白酶-9（MMP-9）在鼻咽癌患者中的预后价值。本研究共纳入99例连续的鼻咽癌患者和40例健康对照。对随访5年的鼻咽癌患者血清IL-8和MMP-9水平进行评估。鼻咽癌患者血清IL-8和MMP-9水平显著高于健康对照（IL-8：26.3[2.9 - 68.0]ng/ml对20.3[2.3 - 38.6]ng/ml，P < 0.001；MMP-9：23.5[3.6 - 52.1]ng/ml对17.3[2.6 - 36.9]ng/ml，P = 0.002）。鼻咽癌患者血清IL-8和MMP-9水平与N分期（IL-8，P = 0.041；MMP-9，P < 0.001）和临床分期（IL-8，P = 0.022；MMP-9，P < 0.001）呈正相关。采用Kaplan-Meier法分析表明，IL-8或MMP-9水平高的患者总生存期（OS）（IL-8，P = 0.012；MMP-9，P < 0.001）和无病生存期（DFS）（IL-8，P = 0.021；MMP-9，P = 0.003）时间显著短于MMP-9或IL-8水平低的患者。单因素和多因素分析显示，MMP-9水平升高是OS和DFS缩短的独立预测因素。MMP-9和IL-8均参与鼻咽癌进展。血清MMP-9可能是鼻咽癌患者预后评估的临床有用指标。
